Study on the transdermal absorption of traditional Chinese medicine ingredients of freckle tight wrinkle essence and its freckle removing mechanism

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200062086

Enrollment

Unknown

Registered

2022-07-21

Start date

2022-07-22

Completion date

Unknown

Last updated

2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

melasma

Interventions

1:placebo,1ml/ time, 2 times / day

2:freckle tight wrinkle essence,1ml / time, 2 times / day

Eligibility

Sex/Gender

All

Age

20 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Age 20 ~ 60 years old; 2. It meets the clinical diagnostic criteria for melasma: (1) Light brown to dark brown, well-defined patches on the face, usually symmetrically distributed, without inflammatory manifestations and scales; (2) No obvious symptoms; (3) Female multiple, mainly occurring after puberty; (4) The condition can be seasonal, often summer is heavier than winter; (5) It excludes pigmentation caused by other diseases (such as zygomatic Brown cyanosis nevus, Riehl melanosis, pigmented actinic lichen planus, etc.) 3. Volunteer to participate in this study and sign the treatment consent form, and be able to follow the doctor's advice during the treatment process.

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women; 2. Scar constitution and allergic constitution; 3. Complicated with heart, lung, liver, kidney, hematopoietic system, malignant tumors, infectious diseases, and other serious diseases; 4. Exclude other diseases (such as naevus fuscocyanus zygomaticus, Riel melanosis, pigmented lichen planus, freckles, coffee spots, post-inflammatory pigmentation, nevus of Ota, etc.); 5. Drugs for chloasma were taken orally or locally within 3 months; 6. Use photon or laser to treat chloasma within 6 months; 7. Patients who are taking drugs that may affect the treatment of chloasma (contraceptives, thyroxine, estrogen), photosensitive drugs; 8. Combined with a bacterial and fungal infection, or local skin damage and superficial ulcer; 9. Those who are taking anticoagulant drugs and have coagulation dysfunction; 10. Patients with autoimmune diseases (such as dermatomyositis, systemic lupus erythematosus, pemphigus, etc.) and mental disorders.

Design outcomes

Primary

Measure	Time frame
Melasma area and severity score(MASI);	—

Secondary

Measure	Time frame
Skin wrinkle score;ITA°;	—

Countries

China

Contacts

Public ContactTao Haiyan

taohaiyan115@163.com+86 13285314292

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026